Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes

Cancer Research

Volumn 58, Issue 20, 1998, Pages 4673-4681

  Ganss, Ruth ^a,b   Hanahan, Douglas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOTOXICITY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNOLOGY; TUMOR VASCULARIZATION;

ADENOMA, ISLET CELL; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; IMMUNOTHERAPY, ADOPTIVE; INSULIN; ISLETS OF LANGERHANS; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; PANCREATIC NEOPLASMS; SIMIAN VIRUS 40; T-LYMPHOCYTES;

EID: 0032532318     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Jaffee, E. M., and Pardoll, D. M. Murine tumor antigens: is it worth the search? Curr. Opin. Immunol., 8: 622-627, 1996.
2. Greenberg, D. P. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol., 49: 281-355, 1991.
3. Restifo, N. P., Kawakami, Y., Marincola, F., Shamamian, P., Taggarse, A., Esquivel, F., and Rosenberg, S. A. Molecular mechanisms used by tumors to escape immune recognition: immunogene therapy and the cell biology of major histocompatibility complex class I. J. Immunother., 14: 182-190, 1993.
4. Chen, L., Linsley, P. S., and Hellström, K. E. Costimulation of T cells for tumor immunity. Immunol. Today, 14: 483-486, 1993.
5. Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., and Linsley, P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71: 1093-1102, 1992.
6. Baskar, S., Ostrand-Rosenberg, S., Nabavi, N., Nadler, L. M., Greeman, G. J., and Glimcher, L. H. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA, 90: 5687-5690, 1993.
7. + T cells by B7-transfected melanoma cells. Science (Washington DC), 259: 368-370, 1993.
8. Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellström, I., and Hellström, K. E. Tumor immunogenicity determines the effect of B7 Costimulation on T cell-mediated tumor immunity. J. Exp. Med., 179: 523-532, 1994.
9. Strand, S., Hofmann, W. J., Hug, H., Müller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., and Galle, P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat. Med., 2: 1361-1366, 1996.
10. Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J-C., and Tschopp, J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (Washington DC), 274: 1363-1366, 1996.
11. Torre-Amione, G., Beauchamp, R. D., Koeppen, H., Park, B. H., Schreiber, H., Moses, H. L., and Rowley, D. A. A highly immunogenic tumor transfected with a murine TGF-β cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA, 87: 1468-1490, 1990.
12. Wick, M., Dubey, P., Koeppen, H., Siegel, C. T., Fields, P. E., Chen, L., Bluestone, J. A., and Schreiber, H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med., 186: 229-238, 1997.
13. Ye, X., McCarrick, J., Jewett, L., and Knowles, B. B. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. USA, 91: 3916-3920, 1994.
14. Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., Faienza-McKall, K., Odermatt, B., Hanahan, D., Zinkernagel, R. M., and Ohashi, P. S. Tumor antigens of peripheral solid tumors do not activate naive or primed T cell: implications for immunotherapy and autoimmune disease. J. Exp. Med., 186: 645-653, 1997.
15. Boon, T., and van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183: 725-729, 1996.
16. Wu, N. Z., Klitzman, B., Dodge, R., and Dewhirst, M. W. Diminished leukocyteendothelium interaction in tumor microvessels. Cancer Res., 52: 4265-4268, 1992.
17. Melder, R, J., Koenig, G. C., Witwer, B. P., Safabakhsh, N., Munn, L. L., and Jain, R. K. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med., 2: 992-997, 1996.
18. Dellian, M., Witwer, B. P., Salehi, H. A., Yuan, F., and Jain, R. K. Quantitation and physiological characterization of anigogenic vessels in mice. Am. J. Pathol., 149: 59-71, 1996.
19. Hanahan, D. Heritable formation of pancreatic beta cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (Lond.), 315: 115-122, 1985.
20. Adams, T. E., Alpert, S., and Hanahan, D. Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic β cells. Nature (Lond.), 325: 223-228, 1987.
21. + T cells specific for a pancreatic β cell neo-antigen. Immunity, 2: 573-585, 1995.
22. Onrust, S. V., Hartl, P., Rosen, S. D., and Hanahan, D. Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J. Clin. Invest., 97: 54-64, 1996.
23. Girard, J-P., and Springer, T. A. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol. Today, 16: 449-457, 1995.
24. Guerder, S., Picarella, D. E., Linsley, P. S., and Flavell, R. A. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor a leads to autoimmunity in transgenic mice. Proc. Natl. Acad. Sci. USA, 91: 5138-5142, 1994.
25. Mombaerts, P., Jacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S., and Papaioannou, V. E. RAG-1 deficient mice have no mature B and T lymphocytes. Cell, 68: 869-877, 1992.
26. Förster, I., and Lieberam, I. Peripheral tolerance of CD4 T cells following local activation in adolescent mice. Eur. J. Immunol., 26: 3194-3202, 1996.
27. Streeter, P. R., Rouse, B. T. N., and Butcher, E. C. Immunohistologic and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymph nodes. J. Cell. Biol., 107: 1853-1862, 1988.
28. Pavlovic, D., van de Winkel, M., van der Auwera, B., Chen, M. C., Schuit, F., Bouwens, L., and Pipeleers, D. Effect of interferon-γ and glucose on major histocompatibility complex class I and class II expression by pancreatic β- and non-β-cells. J. Clin. Endocrinol. Metab., 82: 2329-2336, 1997.
29. Baekkeskov, S., Kanatsuna, T., Klareskog, L., Nielsen, D. A., Peterson, P. A., Rubenstein, A. H., Steiner, D. F., and Lernmark, A. Expression of major histocompatibility antigens on pancreatic islet cells. Proc. Natl. Acad. Sci. USA, 78: 6456-6460, 1981.
30. Radvanyi, F., Christgau, S., Baekkeskov, S., Jolicoeur, C., and Hanahan, D. Pancreatic β cells cultured from individual preneoplastic foci in a multistage tumorigenesis pathway: a potentially general technique for isolating physiologically representative cell lines. Mol. Cell. Biol., 13: 4223-4232, 1993.
31. Sandgren, E. P., Palmiter, R. D., Heckel, J. L., Daugherty, C. C., Brinster, R. L., and Degen, J. L. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell, 66: 245-256, 1991.
32. Wu, T-C., Huang, A. Y. C., Jaffee, E. M., Levitsky, H. I., and Pardoll, D. M. A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med., 182: 1415-1421, 1995.
33. Hallahan, D. E., and Virudachalam, S. Intercellular adhesion molecule 1 knockout abrogates radiation induced pulmonary inflammation. Proc. Natl. Acad. Sci. USA, 94: 6432-6437, 1997.
34. Limmer, A., Sacher, T., Alferink, J., Kretschmar, M., Schönrich, G., Nichterlein, T., Arnold, B., and Hämmerling, G. J. Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment. Eur. J. Immunol., 28: 2395-2406, 1998.
35. + cytotoxic T-lymphocyte activation in mice. Cancer Res., 56: 5005-5011, 1996.
36. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the anigogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
37. Griffioen, A. W., Damen, C. A., Martinotti, S., Blijham, G. H., and Groenewegen, G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res., 56: 1111-1117, 1996.
38. Griffioen, A. W., Damen, C. A., Blijham, G. H., and Groenewegen, G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood, 88: 667-673, 1996.
39. Fukumura, D., Yuan, F., Endo, M., and Jain, R. K. Role of nitric oxide in tumor microcirculation. Am. J. Pathol., 150: 713-725, 1997.
40. Jain, R. K., and Baxter, L. T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res., 48: 7022-7032, 1988.
41. Melief, C. J. M., Offringa, R., Toes, R. E. M., and Martin, W. Peptide-based cancer vaccines. Cur. Opin. Immunol., 8: 651-657, 1996.